 Home > Active Ingredient News > Antitumor Therapy > NEJM: Olapani Treats Metastatic Drug-resistant Prostate Cancer

NEJM: Olapani Treats Metastatic Drug-resistant Prostate Cancer

 Last Update: 2020-05-29
 Source: Internet
 Author: User

Tags

1 4 bdo

phase 4 trial

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Multiple cancers are associated with polysephonic (diphosphate adenosine-ribose) polymerase (PARP), and researchers recently looked at the effectiveness of Orapani's treatment for prostate cancer
this study is a Phase III clinical study to assess the efficacy of PARP inhibitor Olapani in patients with metastatic resistance to prostate cancer, patients receiving The progression of the disease after enheruamine or abitron, based on genetic sequencing, layered patients: queue A (245 patients) had at least 1 BRCA1, BRCA2, or ATM mutation; Patients were randomly accepted for Orapani, enmeluamine, or abitron, and the main endpoint of the study was the progressionless survival rate of imagingin queue A, the image-based progression survival was significantly longer than in the control group (7.4 vs 3.6 months; risk ratio of progress ion or death: 0.34); The total lifetime of the A-list edgy Orapani group in queue A was 18.5 months and the control group was 15.1 monthsEighty-one percent of the progression patients in the control group received Orapani treatmentThroughout the population (queues A and B), the progression-free survival rate based on the Orapani group's imaging also benefited significantlyThe main adverse events of Orapani treatment are anemia and nauseastudies have found that the progression of metastatic detofied prostate cancer after treatment of enmelua or abitron can significantly improve the progressionless survival of patients with no progression

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.